cabazitaxel,177lu-psma-617
emcure,sanofi,novartis
['crpc', 'cabazitaxel']
#therap: 177lu-psma-617 (lupsma) vs cabazitaxel in #mcrpc progressing after docetaxel - os after median follow-up of 3 years (anzup 1603). presentation by . #asco22 written coverage by &gt; 
Largest global online community of #urological medical professionals & patients. #AUA22 #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology